Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949494 · ClinicalTrials.gov registry record · Phase 1
Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)
A Phase 1 study, sponsored by Endeavor Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00949494 is a Phase 1 study that has completed, run by Endeavor Health. The registered enrollment target is 30 participants.
The verdict
NCT00949494, a Phase 1 study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative used to treat knee osteoarthritis (OA). Animal studies have shown that Synvisc can have favorable effects on cartilage when injected into joints. This study attempts to evaluate the effects of Synvisc when injected into knees of patients with knee OA by means of a specialized MRI technology (dGEMRIC).
Interventions
- DEVICE Synvisc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949494
The ClinicalTrials.gov registry entry for NCT00949494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Synvisc is the first listed.
NCT00949494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949494 about?
NCT00949494 is a clinical study titled "Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)". Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative used to treat knee osteoarthritis (OA). Animal studies have shown that Synvisc can have favorable effects on cartilage when injected into joints. This study attempts to evaluate the effects of Synvisc when injected into knees of patien...
What is the current status of trial NCT00949494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00949494?
The interventions under investigation include: Synvisc (DEVICE).
Who is sponsoring clinical trial NCT00949494?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.